HER2 staining of breast cancer is reduced under the current protocol of Ventana PATHWAY anti-HER-2/neu (4B5)

Pathol Int. 2024 Feb;74(2):99-101. doi: 10.1111/pin.13404. Epub 2024 Jan 10.

Authors

Yoshiya Horimoto^{1

2

3}, Hiroko Onagi¹, Junichiro Watanabe², Takuo Hayashi^{1

4}

Affiliations

¹ Department of Human Pathology, Faculty of Medicine, Juntendo University, Tokyo, Japan.
² Department of Breast Oncology, Faculty of Medicine, Juntendo University, Tokyo, Japan.
³ Department of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, Japan.
⁴ Department of Diagnostic Pathology, Juntendo University Hospital, Tokyo, Japan.

PMID: 38197542
DOI: 10.1111/pin.13404

No abstract available

Publication types

Letter

MeSH terms

Breast Neoplasms* / metabolism
Female
Humans
Immunohistochemistry
Receptor, ErbB-2 / metabolism
Staining and Labeling

Substances

Receptor, ErbB-2